You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

exemplifies a process that could benefit from AI enhancements. The integration of AI into drug submission and approval processes is recognised as a pivotal force within the pharmaceutical industry.

Patented genetics from Charlotte’s Web were used in the process. There are very rare instances when cannabis-based drug candidates have achieved FDA approval, with only one containing cannabis ...

India has approved a "living drug" for blood cancer patients, who suffer from an advanced or relapsed stage of the disease, as per The Print. Bengaluru-based biotech startup Immuneel Therapeutics has ...

First-in-class drugs are therapies that utilize novel mechanisms of action, offering new approaches to challenging diseases. In 2024, the U.S. Food and Drug Administration (FDA) approved 50 new ...

Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance ... at an infusion center in almost an hour-long process. The companies said that modeling simulations ...

HSBC India on Friday announced that it has received approval from the Reserve Bank of India (RBI) to open 20 new bank branches in key cities. The new branches will be in cities identified for ...

The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in 2024. On 15 January, the two agencies ...

The second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood cancer patients. Listen to Story Qartemi is India's second CAR-T cell therapy ...

The FDA is reviewing the resubmitted NDA for SPN-830, an apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in adults with Parkinson disease. SPN-830 ...